EFFECTIVENESS OF BOTULINUM TOXIN TYPE A INJECTION ON MODERATE TO SEVERE GLABELLAR LINES SYSTEMATIC REVIEW AND METAANALYSIS: GLABELLAR LINE SCALE PARAMETER STUDY

Effectiveness of Botulinum Toxin Type A Injection on Moderate to Severe Glabellar Lines Systematic Review and Metaanalysis: Glabellar Line Scale Parameter Study

Meiza^1*, Diah Adriani Malik², Puguh Riyanto³, Asih Budiastuti⁴, Retno Indar Widayati⁵, Muslimin⁶, Suhartono⁷

^1,2,3,4,5,6 Departement of Dermatovenereology, Faculty of Medicine, Diponegoro University/ Dr. Kariadi General Hospital Medical Center, Jl. Dr. Sutomo No.16, 50244, Semarang, Indonesia. ⁷Departement of Public Health, Faculty of Medicine, Diponegoro University, Jl. Prof. Soedarto, Tembalang, 50275, Semarang, Indonesia.

Background: Glabellar lines have social and psychological implication since oftentimes generate negative facial expressions that could be misunderstood, such as anger, anxiety, fear or sadness, and others related to extrinsic aging signs. Botulinum toxin type A has been used for more than 20 years in aesthetic medicine and one of many options to improve dynamic facial lines on upper third of the face, including glabellar lines. On April 2009. FDA approved abobotulinum toksin A (Dysport) as the latest botulinum toxin type A, a purified complex diluted with human serum albumin and lactose.

Aim: The purpose of this study is to analyze the effectiveness of botulinum toxin type A (abobotulinum toxin A) as a therapy for moderate to severe glabellar lines.

Methods: searching the electronic database Pubmed-MEDLINE, Scopus, ProQuest, Cochrane library, ClinicalTrials.gov, and Google Scholar, found five articles (n=1.134) included in qualitative and quantitave analysis.

Result: Metaanalysis showed the value of Q statistic was z value = 9,079 (p=0,000). Glabellar lines improvement according to Glabellar Lines Scale were more prominent in botulinum toxin type A injection group compared to control group on the 30th day after botulinum toxin type A injection (relative risk 23,007; CI 95%,11,692 – 45,274). The result of the overall metanalysis showed that glabellar lines severity in the group with botulinum toxin type A injection was significantly improved compared to control group.

Conclusion: Botulinum toxin type A 50 U (abobotulinum toxin type A) is effective in significantly improving glabellar lines severity compared to placebo group

Keywords: botulinum toxin type A, glabellar lines, Glabellar Lines Scale

Free Full-text PDF

How to cite this article:
Meiza, Diah Adriani Malik, Puguh Riyanto, Asih Budiastuti, Retno Indar Widayati, Muslimin, Suhartono .Effectiveness of Botulinum Toxin Type A Injection on Moderate to Severe Glabellar Lines Systematic Review and Metaanalysis: Glabellar Line Scale Parameter Study .American Journal of Dermatological Research and Reviews, 2022, 5:53. DOI: 10.28933/ajodrr-2022-06-0105me

References:

1. McCall-Perez F, Stephens TJ, Herndon JH. Efficacy and tolerability of a facial serum for fine lines, wrinkles, and photodamaged skin efficacy and tolerability of a facial serum for fine lines, wrinkles, and photodamaged skin. J Clin Aesthet Dermatol. 2011;4(7):51–4.
2. Richard Weller Hhamm. Clinical dermatology. 5th ed. wiley Blackwell; 2015.
3. Kim H-J, Seo KK, Lee H-K, Kim J. Clinical Anatomy of the Face for Filler and Botulinum Toxin Injection. Clinical Anatomy of the Face for Filler and Botulinum Toxin Injection. 2016.
4. Gubanova E, Haddad Tabet M, Bergerova Y, Moiseieva O, Chemeris A, Sanches E, et al. Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport®/Azzalure®): Primary Results of the APPEAL Noninterventional Study. Aesthetic Plast Surg [Internet]. 2018;42(6):1672–80. Available from: https://doi.org/10.1007/s00266-018-1200-4
5. Narins RS, Brandt FS, Cohen JL, Donofrio LM, Downie J, Mcdaniel DH, et al. Trial Investigating the Efficacy and Safety of Using a Stringent Composite Endpoint. 2013;891–9.
6. Molina B, Grangier Y, Mole B, Ribe N, Martín Diaz L, Prager W, et al. Patient satisfaction after the treatment of glabellar lines with Botulinum toxin type A (Speywood Unit): A multi-centre European observational study. J Eur Acad Dermatology Venereol. 2015;29(7):1382–8.
7. Kroumpouzos G, Kassir M, Gupta M, Patil A, Goldust M. Complications of Botulinum toxin A: An update review. J Cosmet Dermatol. 2021;20(6):1585–90.
8. Sethi N, Singh S, DeBoulle K, Rahman E. A Review of Complications Due to the Use of Botulinum Toxin A for Cosmetic Indications. Aesthetic Plast Surg [Internet]. 2021;45(3):1210–20. Available from: https://doi.org/10.1007/s00266-020-01983-w
9. Hexsel D, Cartier H, Hedén P, Delmar H, Bergentz P, Camozzato F, et al. Efficacy, safety, and subject satisfaction after abobotulinumtoxina treatment of upper facial lines. Dermatologic Surg. 2018;44(12):1555–64.
10. Lines G, Monheit GD, Baumann L, Maas C, Rand R. Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines. 2020;61–9.
11. Ascher B, Kestemont P, Boineau D, Bodokh I, Stein A, Heckmann M, et al. Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines : A Randomized , Double-Blind , Placebo- and Active Comparator-Controlled Trial. 2018;38(2):183–91.
12. Brandt,Fredric, Swanson Neil, Bauman L HB. Randomized, Placebo-Controlled Study of a New Botulinum Toxin Type A for Treatment of Glabellar Lines: Efficacy and Safety. 2009;1893–901.
13. Ascher Benjamin, Rzany B, Kestemont P et all. Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Linesitle. Aesthetic Surg J. 2019;
14. Joel Schlessinger, Daniel P. Friedmann Daniel P, Mayoral Flor E. AbobotulinumtoxinA Treatment of Glabellar Lines Using a New Reconstitution and Injection Volume: Randomized, Placebo-Controlled Data. 2021.
15. Kestemont P, Hilton S, Andriopoulos B, Prygova I, Thompson C, Volteau M. Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines : A Phase III , Double-Blind , Randomized , Placebo-Controlled and Open-Label Study. 2022;42(3):301–13.
16. Coleman K. Botulinum Toxin in Facial Rejuvenation. Philadelphia: Elsevier Inc; 2020.
17. Nestor M, Ablon G, Pickett A. Key parameters for the use of abobotulinumtoxina in aesthetics: Onset and duration. Aesthetic Surg J. 2017;37:S20–31.
18. Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W. Efficacy and Safety of 3- and 5-Injection Patterns (30 and 50 U) of Botulinum Toxin A (Dysport) for the Treatment of Wrinkles in the Glabella and the Central Forehead Region. 2015;142.
19. De Maio M, Rzany B. Injectable fillers in aesthetic medicine. Injectable Fillers in Aesthetic Medicine. 2014. 1–174 p.
20. Manríquez JJ, Cataldo K, Vera-Kellet C, Harz-Fresno I. Wrinkles. BMJ Clin Evid. 2014;2014(February):1–47.
21. Schlessinger J, Cohen JL, Shamban A, Jacob C, Karimi K, Maas C, et al. A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines. Dermatol Surg. 2021;47(4):504–9.
22. Guo Y. Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects : Results From 2 Identical Phase III Studies. 2019;1381–93.
23. Carruthers A, Carruthers J. Coleman William P et all. Multicenter, Randomized, Phase III Study of a Single Dose of IncobotulinumtoxinA, Free from Complexing Proteins, in the Treatment of Glabellar Frown Lines. 2013;551–8.
24. Jones D, Carruthers J, Narins RS, Coleman WP, Harrington L, Brandt FS, et al. Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: A post hoc pooled analysis of 2 randomized, placebo-controlled, Phase 3 trials. Dermatologic Surg. 2014;40(7):776–85.
25. Liu T, Ph D, Yang Q. Efficacy and Safety of Botulinum Toxin. 2015;310–8.